Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Thomas H. Howard, MD
Healthcare Provider Co-Director
UAB Comprehensive Sickle Cell Center
ACC 512
1600 Seventh Avenue South
Birmingham, Alabama, United States
Dr. Howard is Professor of Pediatrics and Director of Hematology Section at University of Alabama. Dr. Howard hails from North Carolina, graduated from the University of North Carolina at Chapel Hill in Chemistry, and received his MD degree from the Johns Hopkins University School of Medicine (JHUSOM). Dr. Howard’s primary clinical interest is general hematology with a focus on sickle cell disease (SCD), hemophilia and red and white blood cell defects. Dr. Howard’s research career interests and experience include an NIH funded basic research program focused on assembly and regulation of the molecular motor in neutrophils; his clinical research focuses on neurological abnormalities, health care delivery, and novel therapies for SCD.
Currently he is institutional PI for NHLBI studies (The Baby Hydroxyurea Trial, Co-PI on the JHU/UAB Basic and Translational Research Program, The JHU Priapism Project), NINDS grants (The Silent Infarct Transfusion Trial, Hydroxyurea for Silent Infarcts in Sickle Hemoglobinopathies), and HRSA projects (Sickle Cell Treatment Demonstration Project) and industry sponsored trials of a novel pneumococcal vaccine. He, in collaboration with Lee Hilliard MD, founded and developed the Children and Youth Sickle Network (The CYSNTM), a network of regional, comprehensive SCD clinics focused on prevention of SCD morbidity and mortality.
+myBinderRelated Content
-
Ward Hagar, MDDr. Hagar is the Director of Adult Sickl...
-
Yogen Saunthararajah, MDYogen Saunthararajah, MD, is a staff in ...
-
Gene-Therapy Company Crispr Drops as FDA Puts Trial on HoldCrispr Therapeutics AG plunged after the...
-
A randomized controlled trial comparing two vaso-occlusive episode (VOE) protocols in sickle cell disease (SCD)Limited evidence guides opioid dosing st...
-
Winthrop-University HospitalNYU Winthrop's pediatric hematologists p...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
-
Sickle Cell Disease Coalition (SCDC)https://www.youtube.com/watch?v=oQP-Uq0B...
